In accordance with Section 3 of the Articles of Association of Orion Corporation, 100,000 A shares have been converted into 100,000 B shares. The conversion has been entered into the Trade Register on 14 July 2016.
The total number of shares in Orion Corporation is 141,257,828 which, after the conversion, consists of 38,581,154 A shares and 102,676,674 B shares.
| Olli Huotari |
SVP, Corporate Functions
| Jari Karlson |
Tuukka Hirvonen, Manager, Investor Relations & Financial Communications, tel. +358 10 426 2721
Orionintie 1A, FI-02200 Espoo, Finland
Orion is a globally operating Finnish company developing pharmaceuticals and diagnostic tests - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory for which Orion developes inhaled Easyhaler® pulmonary drugs.
Orion's net sales in 2015 amounted to EUR 1,016 million and the company had about 3,400 employees. Orion's A and B shares are listed on Nasdaq Helsinki.